NCT05464576Recruiting
Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis
Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis.
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
Urinary bladder tumors with a frequency of 13000 new cases a year, have a heterogeneity in terms of survival according to the stage of local flooding. This is an aggressive tumor because of the potential muscular infiltration. It seems important in this case (muscular invasion), to increase the global survival. The anatomopathological analysis of the TURB (biopsy byTrans-Urethral Resection of the Bladder) is actually the gold standard for the pathology of bladder tumor. No need an imaging to discuss about the small and non muscular invasive tumor. But in most cases, the use is to perform at last an ultrasound or a CT-Scan, specially for the invasive tumor. A lot of studies show that CT SCAN. is not the best way of investigation for the bladder muscle invasion. However, as in the prostate cancer with the PIRADS Score, the MRI can be useful for the bladder, thanks to the sequence improvement to the machine. The study from Panebianco 2018, starts to talk about the MRI in the urinary bladder cancer with new radiological terms. It creates a new score called VIRADS score (as the PIRADS score already used for the prostate cancer). But it is never compared with the results of the TURB. Our study compares the results of the MRI pre operative versus the pathology results on prospective analysis. Main objective : T tumoral score in urinary bladder tumor : MRI versus pathology results. Secondary objectives : the contribution of diffusion weighted MRI in the bladder neoplasm. Type of study : interventional study, prospective, mono centric, single arm, intent-to-treat
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 12 Jul 2022
- Start date
- 14 Sept 2022
- Primary completion date
- 14 Mar 2028
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Bladder cancer
- NCT number
- NCT05464576
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 14 Sept 2022 to the primary completion date, 14 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- MRI contraindication : pacemaker, heart valve, clips, stents, coils, non-MRI compatible defibrillators, neural or peripheral stimulator, cochlear implant, intraocular foreign body, claustrophobia
- Allergy to gadolinium (contrast product necessary for carrying out the MRI), hypersensitivity to gadoteric acid or gadolinated contrast products, to meglumine
- Suspicion of an infectious disease such as schistosomiasis (differential diagnosis)
Other
- Participation refusal
- Patient under guardianship, deprived of liberty, impaired understanding
- Pregnant/breastfeeding woman
- Patient presenting with macroscopic clotting hematuria on the day of the MRI
Who the study is looking for
- Patient, male or female, aged \>18ans
- Benefiting from Social Security
- Urinary bladder tumour confirmed on cystoscopy and requiring a TURB
- Understanding and reading French well
- Ability to give informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.